Shuganning Injection Incorporated into the Interpretation of Clinical Pathway, 2018 Edition-Infectious Diseases

-- Get the recommend medication of "hepatitis A", "acute hepatitis B" and "chronic hepatitis B" clinical treatment programs

Shuganning injection has been specially recommend in the clinical diagnosis and treatment of "hepatitis A", "acute hepatitis B" and "chronic hepatitis B" in the clinical pathway interpretation of infectious diseases, which shows that Shuganning has good safety in the diagnosis and treatment of viral hepatitis, and its effectiveness has been widely recognized and affirmed by doctors and patients.

"Shuganning Injection" was selected into the Interpretation of Clinical Pathway (2018 edition, Infectious Diseases fascicle), and together with the Interpretation of Clinical Pathway (2018 edition, Digestive Diseases fascicle), it was recommend as five clinical therapeutic drugs for liver diseases ("drug-induced liver injury" and "cholestatic jaundice" in the digestive fascicle ", infectious diseases fascicle" hepatitis A "," acute hepatitis B "," chronic hepatitis B "), for clinical diagnosis and treatment of liver disease provides more options.